- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Zhengye Biotechnology regains Nasdaq bid price compliance; shares down | 2 | Seeking Alpha | ||
| 22.07. | Zhengye Biotechnology Stock Plunges Following 322% Rally In Volatile Reversal | 18 | Benzinga.com | ||
| 21.07. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.07. | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | 909 | AFX News | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.07. | Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity | 362 | GlobeNewswire (Europe) | Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 04.06. | Zhengye Biotechnology receives Nasdaq bid price deficiency notice | 2 | Investing.com | ||
| 04.06. | Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 201 | GlobeNewswire (Europe) | Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 04.06. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.04. | Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results | 271 | PR Newswire | JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer... ► Artikel lesen | |
| 28.04. | Zhengye Biotechnology Holding Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 06.04. | Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure | 303 | GlobeNewswire (Europe) | Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 10.02. | Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders | 958 | GlobeNewswire (Europe) | Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 14,660 | +1,58 % | Piper Sandler raises Viatris stock price target on patch growth | ||
| SYNBIOTIC | 0,852 | -1,27 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,170 | +0,99 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,000 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 9,920 | +1,43 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,350 | -0,74 % | OPKO Health: Strategiewechsel hin zu Therapeutika, gestützt durch hohe Liquidität | ||
| XORTX THERAPEUTICS | 1,558 | -4,39 % | XORTX Therapeutics Inc.: XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO | ? Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ? CALGARY, Alberta, Sept. 10, 2026 (GLOBE... ► Artikel lesen | |
| OPUS GENETICS | 4,700 | -6,00 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement... ► Artikel lesen | |
| SOLIGENIX | 0,362 | +0,53 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| TALPHERA | 1,010 | -3,81 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,576 | +0,11 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| SCYNEXIS | 3,745 | -2,60 % | SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer | JERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for... ► Artikel lesen | |
| PROTHENA | 7,244 | +0,19 % | Prothena Corporation plc: Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,935 | +1,94 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Completion of Redomiciliation to Delaware | CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,770 | +0,57 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers | TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel... ► Artikel lesen |
Das Unternehmen ZHENGYE BIOTECHNOLOGY HOLDING LIMITED kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,72 % bei einem Aktienkurs von 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHENGYE BIOTECHNOLOGY HOLDING LIMITED finden Sie auf Wallstreet Online.